Table 2.

Summary of comparative outcomes of locoregional treatments from recent studies.

Abbreviations: SBRT = stereotactic body radiotherapy; TACE = transarterial chemoembolization; CP = Child-Pugh; NR = not reported; CTCAE = Common Terminology Criteria for Adverse Events; TAE = transarterial embolization; BCLC = Barcelona Clinic Liver Cancer; KPS = Karnofsky Performance Status; RFA = radiofrequency ablation; ECOG = Eastern Cooperative Oncology Group; QLQ-C30 = EORTC Core Quality-of-Life Questionnaire; QLQ-HCC18 = EORTC Quality-of-Life Questionnaire – Hepatocellular Carcinoma/Primary Liver Cancer Module; EQ-5D = European Quality-of-Life 5 Dimensions Questionnaire; PS = performance status; PIQ-6 = Pain Item Questionnaire (6 itmes); PCS = physical component summary of Short Form 36 (SF-36) Health Survey; MCS = mental component summary of Short Form 36 (SF-36) Health Survey; USD = United States Dollars; FFLP = freedom from local progression; GI = gastrointestinal; CLRR = cumulative local recurrence rate; LC = local control; CMR = cumulative mortality rate; OS = overall survival; HCC = hepatocellular carcinoma; TARE = transarterial radioembolization; ST = systemic therapy; MVI = macrovascular invasion; FACT-Hep = Functional Assessment of Cancer Therapy - Hepatobiliary.

* Post-hoc, per-protocol analysis.

^** Assuming 60 patient per year.

^*** After adjustment for PS, metastases, CP-A5 vs 6, degree of MVI.